丹麦跨性别者与顺性别者的精神与躯体健康比较
该登记-based全国队列纳入2000年1月1日至2021年12月31日丹麦3812名跨性别者(跨性别男性化1993人,中位年龄19岁[IQR 15-24];跨性别女性化1819人,中位年龄23岁[IQR 19-33])及38120名年龄匹配顺性别对照(每名跨性别者配5男5女),比较首次跨性别接触码前5年内精神与躯体疾病诊断及药物使用。跨性别者精神疾病诊断比值比最高达12倍,神经症/应激相关障碍、发育障碍(含孤独症)、心境障碍、行为障碍最常见;跨性别男性化者糖尿病、哮喘(含COPD)、损伤中毒、疼痛诊断更多,跨性别女性化者感染、贫血、糖尿病、睡眠呼吸暂停、疼痛更多;精神药物、抗酸药、泻药使用也更高。作者认为精神与躯体共病应作为跨性别照护的整合部分。
要点
- 跨性别者精神疾病诊断比值比最高达12倍,神经症/应激相关障碍跨性别男性化AOR 4.70(95%CI 4.02-5.50)、跨性别女性化AOR 5.27(95%CI 4.28-6.49)。
- 发育障碍(含孤独症)跨性别男性化AOR 11.67(95%CI 8.85-15.39)、跨性别女性化AOR 9.39(95%CI 7.05-12.50),心境障碍跨性别男性化AOR 5.41(95%CI 4.32-6.77)、跨性别女性化AOR 5.61(95%CI 4.16-7.57)。
- 跨性别男性化者较对照顺性别女性糖尿病AOR 2.00(95%CI 1.12-3.56)、哮喘(含COPD)AOR 1.40(95%CI 1.06-1.85)、损伤中毒AOR 1.28(95%CI 1.15-1.41)、疼痛AOR 1.29(95%CI 1.12-1.49)。
- 跨性别女性化者较对照顺性别男性感染AOR 1.68(95%CI 1.33-2.13)、贫血AOR 3.08(95%CI 1.36-6.97)、糖尿病AOR 1.95(95%CI 1.25-3.05)、睡眠呼吸暂停AOR 3.41(95%CI 1.84-6.31)、疼痛AOR 1.31(95%CI 1.08-1.58)。
- 精神药物使用:跨性别男性化vs对照顺性别女性抗精神病药AOR 6.20(95%CI 5.07-7.59)、催眠镇静药AOR 4.45(95%CI 3.78-5.23)、抗酸药AOR 1.25(95%CI 1.07-1.45)、泻药AOR 1.53(95%CI 1.17-1.99);
适用人群与场景
- 丹麦全国登记队列,纳入2000年1月1日至2021年12月31日期间首次获得跨性别身份接触码的跨性别者,包括跨性别男性化1993人(52.3%,中位年龄19岁,IQR 15-24岁)和跨性别女性化1819人(47.7%,中位年龄23岁,IQR 19-33岁)。
- 对照为每名跨性别者匹配10名年龄匹配的顺性别者(5名男性、5名女性),共38120名。
- 评估窗口为首次跨性别接触码前5年内的精神与躯体疾病诊断及药物使用。
研究设计与关键结果
- 研究类型:基于登记数据的全国队列研究;样本量:3812名跨性别者与38120名顺性别对照;主要终点为首次跨性别接触码前5年内国际疾病分类第十版诊断码及药物使用。
- 跨性别者精神疾病诊断比值比最高达12倍;神经症/应激相关障碍跨性别男性化AOR 4.70(95%CI 4.02-5.50)、跨性别女性化AOR 5.27(95%CI 4.28-6.49)。
- 发育障碍(含孤独症)跨性别男性化AOR 11.67(95%CI 8.85-15.39)、跨性别女性化AOR 9.39(95%CI 7.05-12.50);心境障碍跨性别男性化AOR 5.41(95%CI 4.32-6.77)、跨性别女性化AOR 5.61(95%CI 4.16-7.57);行为障碍跨性别男性化AOR 4.50(95%CI 3.61-5.62)、跨性别女性化AOR 4.15(95%CI 3.19-5.39)。
- 跨性别男性化者较对照顺性别女性:糖尿病AOR 2.00(95%CI 1.12-3.56)、哮喘(含COPD)AOR 1.40(95%CI 1.06-1.85)、损伤中毒AOR 1.28(95%CI 1.15-1.41)、疼痛AOR 1.29(95%CI 1.12-1.49)。
- 跨性别女性化者较对照顺性别男性:感染AOR 1.68(95%CI 1.33-2.13)、贫血AOR 3.08(95%CI 1.36-6.97)、糖尿病AOR 1.95(95%CI 1.25-3.05)、睡眠呼吸暂停AOR 3.41(95%CI 1.84-6.31)、疼痛AOR 1.31(95%CI 1.08-1.58)。
- 药物使用:跨性别男性化vs对照顺性别女性抗精神病药AOR 6.20(95%CI 5.07-7.59)、催眠镇静药AOR 4.45(95%CI 3.78-5.23)、抗酸药AOR 1.25(95%CI 1.07-1.45)、泻药AOR 1.53(95%CI 1.17-1.99);跨性别女性化vs对照顺性别男性抗精神病药AOR 4.74(95%CI 3.92-5.74)、催眠镇静药AOR 3.01(95%CI 2.53-3.57)、抗酸药AOR 1.32(95%CI 1.12-1.56)。
- 精神健康诊断与精神药物使用与躯体诊断及躯体疾病药物使用共存。
证据类型、等级与局限
- 证据类型:基于登记数据的全国队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,跨性别者的精神与躯体共病应作为跨性别照护的整合部分。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Mental and somatic health is often impaired among transgender persons. Studies regarding coexisting mental and somatic health outcomes among transgender persons are limited.
OBJECTIVE: To assess health diagnoses and medicine use among transgender persons compared with cisgender controls.
DESIGN, SETTING, AND PARTICIPANTS: This register-based national cohort study included data from January 1, 2000, to December 31, 2021. Transgender persons were included on the first date of receipt of a transgender identity contact code. Controls included 10 age-matched cisgender men (n = 5) and women (n = 5) for each transgender person. Statistical analyses were conducted from September to December 2024.
MAIN OUTCOMES AND MEASURES: The main outcomes were International Statistical Classification of Diseases and Related Health Problems, Tenth Revision diagnosis codes and medicine use in a 5-year period up to the first date of transgender contact code for most commonly occurring mental and physical illnesses. The main outcomes were determined after data collection.
RESULTS: The cohort included 3812 transgender persons (1993 transmasculine persons [52.3%] with a median age of 19 years [IQR, 15-24 years] and 1819 transfeminine persons [47.7%] with a median age of 23 years [IQR, 19-33 years]) and 38 120 cisgender controls. The odds for a mental health diagnosis was up to 12 times higher among transgender persons compared with cisgender controls. Among transmasculine and transfeminine persons, neurotic, stress-related disorders (transmasculine: adjusted odds ratio [AOR], 4.70 [95% CI, 4.02-5.50]; transfeminine: AOR, 5.27 [95% CI, 4.28-6.49]); developmental disorders, including autism (transmasculine: AOR, 11.67 [95% CI, 8.85-15.39]; transfeminine: AOR, 9.39 [95% CI, 7.05-12.50]); mood (affective) disorders (transmasculine: AOR, 5.41 [95% CI, 4.32-6.77]; transfeminine: AOR, 5.61 [95% CI, 4.16-7.57]); and behavioral disorders (transmasculine: AOR, 4.50 [95% CI, 3.61-5.62]; transfeminine: AOR, 4.15 [95% CI, 3.19-5.39]) were the most frequent mental health diagnoses compared with cisgender controls of the opposite sex at birth. Transmasculine persons had higher odds for somatic diagnosis codes of diabetes (AOR, 2.00 [95% CI, 1.12-3.56]), asthma (including chronic obstructive lung disease; AOR, 1.40 [95% CI, 1.06-1.85]), injury and poisoning (AOR, 1.28 [95% CI, 1.15-1.41]), and pain (AOR, 1.29 [95% CI, 1.12-1.49]) compared with control cisgender women. Among transfeminine persons, somatic diagnosis codes of infection (AOR, 1.68 [95% CI, 1.33-2.13]), anemia (AOR, 3.08 [95% CI, 1.36-6.97]), diabetes (AOR, 1.95 [95% CI, 1.25-3.05]), sleep apnea (AOR, 3.41 [95% CI, 1.84-6.31]), and pain (AOR, 1.31 [95% CI, 1.08-1.58]) were more frequent compared with control cisgender men. Transgender persons had higher use of psychopharmacologic medicine, antacids, and laxatives compared with cisgender controls (transmasculine persons vs control cisgender women, antipsychotics: AOR, 6.20 [95% CI, 5.07-7.59]; hypnotics-sedatives: AOR, 4.45 [95% CI, 3.78-5.23]; antacids: AOR, 1.25 [95% CI, 1.07-1.45]; and laxatives: AOR, 1.53 [95% CI, 1.17-1.99]; transfeminine persons vs control cisgender men, antipsychotics: AOR, 4.74 [95% CI, 3.92-5.74]; hypnotics-sedatives: AOR, 3.01 [95% CI, 2.53-3.57]; and antacids: AOR, 1.32 [95% CI, 1.12-1.56]). Mental health diagnoses and use of psychopharmacologic drugs were coexisting with somatic diagnoses and use of drugs for somatic diseases.
CONCLUSIONS AND RELEVANCE: This cohort study of Danish transgender persons and cisgender controls found significantly higher risks for mental and somatic health diagnoses among transgender persons. Coexistence of mental health outcomes and somatic health outcomes among transgender persons could be associated with stress encountered due to belonging to a gender identity or sexual orientation minority group; mental and physical morbidity should be considered an integrated part of transgender care.
参考来源
- Glintborg D, Møller JK, Rubin KH, et al. Mental and Physical Health Among Danish Transgender Persons Compared With Cisgender Persons. JAMA Netw Open. 2025. PMID: 40272800. doi:10.1001/jamanetworkopen.2025.7115
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。